18879-80-6

Basic information

• Product Name: 1-(4-IODOPHENYL)-2-THIOUREA
• Synonyms: 1-(p-Iodophenyl)thiourea;1-(4-IODOPHENYL)-2-THIOUREA;4-IODOPHENYLTHIOUREA
• CAS NO: 18879-80-6
• Molecular Formula: C₇H₇IN₂S
• Molecular Weight: 278.11
• Mol File: 18879-80-6.mol
• Article Data: 5

Chemical Properties

• Melting Point: 183 °C
• Boiling Point: 335.2 °C at 760 mmHg
• Flash Point: 156.5 °C
• Appearance: /
• Density: 1.991 g/cm³
• Vapor Pressure: 0.000122mmHg at 25°C
• Refractive Index: 1.798
• CAS DataBase Reference: 1-(4-IODOPHENYL)-2-THIOUREA(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-IODOPHENYL)-2-THIOUREA(18879-80-6)
• EPA Substance Registry System: 1-(4-IODOPHENYL)-2-THIOUREA(18879-80-6)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 18879-80-6(Hazardous Substances Data)

Usage

General Description

1-(4-Iodophenyl)-2-thiourea is a chemical compound that is primarily used in the pharmaceutical industry for its potential as an anti-thyroid agent. It works by inhibiting the synthesis and release of thyroid hormones, which can be beneficial in the treatment of hyperthyroidism and other thyroid disorders. Additionally, it has been studied for its potential anti-inflammatory and anti-cancer properties. Its structure includes a phenyl group with a substituent iodine atom, and a thiourea group, making it an organoiodine compound. However, its potential health hazards and environmental impacts should be carefully considered and researched before any widespread application.

InChI:InChI=1/C7H7IN2S/c8-5-1-3-6(4-2-5)10-7(9)11/h1-4H,(H3,9,10,11)

Upstream product

• 6160-65-2 1,1'-Thiocarbonyldiimidazole 
• 540-37-4 p-aminoiodobenzene 
• 1147550-11-5 ammonium thiocyanate 
• 19249-88-8 N-benzoyl-N'-(4-iodo-phenyl)-thiourea 
• 2059-76-9 4-iodophenyl isothiocyanate 

Downstream Products

• 16582-58-4 6-iodobenzo[d]thiazol-2-amine 
• 21262-26-0 2-(4-iodo-anilino)-thiazol-4-one 
• 855282-75-6 2-chloro-6-iodobenzothiazole 

Relevant articles and documents

Chemical Genetics Reveals a Role of Squalene Synthase in TGFβ Signaling and Cardiomyogenesis

KY02111 is a widely used small molecule that boosts cardiomyogenesis of the mesoderm cells derived from pluripotent stem cells, yet its molecular mechanism of action remains elusive. The present study resolves the initially perplexing effects of KY02111 on Wnt signaling and subsequently identifies squalene synthase (SQS) as a molecular target of KY02111 and its optimized version, KY-I. By disrupting the interaction of SQS with cardiac ER-membrane protein TMEM43, KY02111 impairs TGFβ signaling, but not Wnt signaling, and thereby recapitulates the clinical mutation of TMEM43 that causes arrhythmogenic right ventricular cardiomyopathy (ARVC), an inherited heart disease that involves a substitution of myocardium with fatty tissue. These findings reveal a heretofore undescribed role of SQS in TGFβ signaling and cardiomyogenesis. KY02111 may find its use in ARVC modeling as well as serve as a chemical tool for studying TGFβ/SMAD signaling.

COMPOSITION FOR PROMOTING CARDIAC DIFFERENTIATION OF PLURIPOTENT STEM CELL COMPRISING EGFR INHIBITOR

The present invention provides a composition for promoting cardiac differentiation of a pluripotent stem cell containing an EGFR inhibitor. The present invention also provides a kit for promoting cardiac differentiation containing an EGFR inhibitor and a method for inducing cardiac differentiation of a pluripotent stem cell comprising culturing the pluripotent stem cell in a medium containing an EGFR inhibitor.

Riluzole series. synthesis and in vivo 'antiglutamate' activity of 6- substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines

Two series of analogues of riluzole, a blocker of excitatory amino acid mediated neurotransmission, have been synthesized: monosubstituted 2- benzothiazolamines and 3-substituted derivatives. Of all the compounds prepared in the first series, only 2-benzothiazolamines bearing alkyl, polyfluoroalkyl, or polyfluoroalkoxy substituents in the 6-position showed potent anticonvulsant activity against administration of glutamic acid in rats. The most active compounds displaying in vivo 'antiglutamate' activity were the 6-OCF3 (riluzole), 6-OCF2CF3, 6-CF3, and 6-CF2CF3 substituted derivatives with ED50 values between 2.5 and 3.2 mg/kg i.p. Among the second series of variously substituted benzothiazolines, compounds as active as riluzole or up to 3 times more potent were identified in two series: benzothiazolines bearing a β-dialkylaminoethyl moiety and compounds with an alkylthioalkyl chain and their corresponding sulfoxides and sulfones. The most potent derivatives were 2-imino-3-(2-methylthio)- and 2-imino-3-(2- methylsulfinyl)-ethyl-6-trifluoromethoxybenzothiazolines (61 and 64, ED50 = 1.0 and 1.1 mg/kg i.p., respectively). In addition, intraperitoneal administration of some of the best benzothiazolines protected mice from mortality produced by hypobaric hypoxia.